Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2009

View Archived Issues

Study provides proof-of-principle for OGX-225 in prostate cancer

Micelle-encapsulated formulation of SN-38 shows antitumor activity in vitro and in vivo

GlaxoSmithKline claims glycogen phosphorylase inhibitors as antidiabetic agents

5-HT2A inverse agonists and antagonists patented at ACADIA

Chemokine receptor antagonists for use in Crohn's disease claimed by Encysive Pharmaceuticals

Novel sEH inhibitors for hypertension, heart failure, etc., patented by GSK

Argenta Discovery prepares and tests novel CRTH2 receptor antagonists

Pharma companies gear up to meet new swine influenza demands

Short-dose anti-hepatitis B virus vaccine (HBsAg-ISS) shows comparable immunogenicity to Engerix-B

Almirall presents update on respiratory drugs aclidinium bromide and LAS-100977

Results of 1-year open-label extension study of eslicarbazepine acetate for epilepsy reported

Carisbamate dose-response effect seen in patients with partial onset seizures

Merck & Co. offers Q1 pipeline update

Novel anticancer compound CBS-9106 shows activity in preclinical development

Bioniche updates corporate activities

The pro-apoptotic peptide TM-601 induces regression of choroidal neovascularization lesions in vivo

N-Acetylcysteine amide shows preclinical promise for the treatment of retinal degenerative states

Kinaxo identifies mTOR as a new target of Pfizer's Celebrex

Takara receives Japanese approval for research into HSV-TK gene therapy in leukemia

Tigris initiates dosing in phase I clinical trial of GGTI-2418 in metastatic solid tumors

Intercell delays initiation of phase III TREK study of travelers' diarrhea vaccine patch

Northfield receives complete response from FDA denying approval of PolyHeme BLA

AMRI and CHDI sign drug discovery collaboration in Huntington's disease

FDA approves Novartis' combination drug Exforge HCT for high blood pressure

Almirall and Ironwood sign panEuropean licensing-in agreement for IBS drug linaclotide

FDA approves Solvay's Creon for exocrine pancreatic insufficiency due to CF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...